X4 Pharmaceuticals, Inc

XFOR Nasdaq SEC CIK 1501697
Follow X4 Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.9M +63.1% vs same quarter last year
Net income −$20.2M +32.3% vs same quarter last year
EPS, diluted −$0.16 +76.8% vs same quarter last year
Operating cash flow −$20.2M +27.4% vs same quarter last year
Revenue by quarter
$1.4M
$28.8M
$2M
$1.8M
$2.6M
$2.7M
$8.8M
$2.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$35.1M−$79.2M
FY24$2.6M−$37.5M
FY23$0−$101.2M
FY22$0−$93.9M
FY21$0−$88.7M
FY20$3M−$62.1M
FY19$0−$52.8M
FY18$0−$33.3M
FY17-−$22M
FY16-−$23M
FY15--
MarginsShare of revenue
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−247.4%−225.6%
FY24−1423.6%−1464.6%
FY23--
FY22--
FY21--
FY20−1995.8%−2071%
FY19--
FY18--
FY17--
FY16--
FY15--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$85.6M
FY24−$131.2M
FY23−$96.6M
FY22−$77.2M
FY21−$71.5M
FY20−$60.2M
FY19−$48.2M
FY18−$25.4M
FY17−$21.7M
FY16−$21.7M
FY15-
Returned to shareholdersDividends paid and shares bought back
$0$500K$1M$1.5M$2MFY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23$0
FY22$0
FY21$2M
FY20$0
FY19$0
FY18-
FY17-
FY16-
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • X4 Pharmaceuticals
  • Healthcare median
−3000%−2000%−1000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearX4 PharmaceuticalsHealthcare median
FY25−225.6%−30.6%
FY24−1464.6%−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20−2071%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%